Effective Lenvatinib Treatment Complicated with Secondary Tracheocutaneous Fistula in Patients with Advanced Anaplastic Thyroid Carcinoma

被引：1
|
作者：
Wu, Wen-Chi [1 ]
Lai, Jiun-, I [2 ,3 ]
Chen, Jui-Yu [4 ]
Liu, Chun-Yu [2 ,3 ,5 ]
机构：
[1] Taipei Vet Gen Hosp, Dept Med, Taipei 11217, Taiwan
[2] Natl Yang Ming Univ, Inst Clin Med, Taipei 11221, Taiwan
[3] Taipei Vet Gen Hosp, Dept Oncol, Div Med Oncol, Taipei 11217, Taiwan
[4] Taipei Vet Gen Hosp, Dept Surg, Taipei 11217, Taiwan
[5] Taipei Vet Gen Hosp, Div Transfus Med, Dept Med, Taipei 11217, Taiwan
来源：
REPORTS | 2019年 / 2卷 / 03期
关键词：
lenvatinib; anaplastic thyroid carcinoma (ATC); tracheocutaneous fistula; tumor-cutaneous fistula; carotid blowout syndrome;
D O I：
10.3390/reports2030022
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Anaplastic thyroid carcinoma (ATC) is a fatal disease with a poor prognosis. Lenvatinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) which is approved in Japan for the treatment of ATC. Data of treatment response and adverse effects of lenvatinib in ATC patients is still relatively scarce, especially in non-Japanese patient populations. Here we report dramatic treatment effects of lenvatinib in two patients with stage IVc ATC, who later developed significant morbidities including tracheal perforation and fistula formation. Our cases demonstrate the efficacy and provide cautionary information for treatment of ATC. In treating advanced ATC patients with lenvatinib, close monitoring is highly recommended.
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Lenvatinib and Pembrolizumab as save and effective combination treatment in 8 patients with metastasized anaplastic (ATC) and poorly differentiated thyroid carcinomas (PDTC)
    Dierks, C.
    Miething, C.
    von Bubnoff, N.
    Duyster, J.
    Thomusch, O.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 306 - 306
  • [22] Lung cavitation in patients with anaplastic thyroid cancer treated with lenvatinib
    Murayama, Daisuke
    Yamamoto, Yayoi
    Matsui, Ai
    Yasukawa, Mio
    Okamoto, Saki
    Toda, Soji
    Iwasaki, Hiroyuki
    GLAND SURGERY, 2022, 11 (06) : 963 - 969
  • [23] Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma
    Glen, Hilary
    FUTURE ONCOLOGY, 2016, 12 (19) : 2195 - 2204
  • [24] Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid
    Savvides, Panayiotis
    Nagaiah, Govardhanan
    Lavertu, Pierre
    Fu, Pingfu
    Wright, John J.
    Chapman, Robert
    Wasman, Jay
    Dowlati, Afshin
    Remick, Scot C.
    THYROID, 2013, 23 (05) : 600 - 604
  • [25] Does surgery improve the survival of patients with advanced anaplastic thyroid carcinoma?
    Lu, WT
    Lin, JD
    Huang, HS
    Chao, TC
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1998, 118 (05) : 728 - 731
  • [26] Difficult Tracheotomy in Advanced Anaplastic Thyroid Carcinoma
    Aydin, Sedat
    Paksoy, Mustafa
    Uysal, Elif
    ISTANBUL MEDICAL JOURNAL, 2019, 20 (03): : 250 - 252
  • [27] Multimodality treatment for anaplastic thyroid carcinoma - Treatment outcome in 75 patients
    Swaak-Kragten, Annemarie T.
    de Wilt, Johannes H. W.
    Schmitz, Paul I. M.
    Bontenbal, Marijke
    Levendag, Peter C.
    RADIOTHERAPY AND ONCOLOGY, 2009, 92 (01) : 100 - 104
  • [28] Anaplastic thyroid carcinoma: palliation or treatment?
    Wein, Richard O.
    Weber, Randal S.
    CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2011, 19 (02): : 113 - 118
  • [29] Systemic treatment of anaplastic thyroid carcinoma
    Dierks, Christine
    ONKOLOGIE, 2022, 28 (08): : 642 - 648
  • [30] Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma
    Boudin, Laurys
    Morvan, Jean-Baptiste
    Thariat, Juliette
    Metivier, Denis
    Marcy, Pierre-Yves
    Delarbre, David
    CURRENT ONCOLOGY, 2022, 29 (10) : 7718 - 7731
12345